uniQure N.V. Aktie News

Though positive on an absolute basis, Diamond Hill International Strategy portfolio modestly trailed the benchmark during the quarter. From a sector perspective, health care and information technology contributed most to relative performance, while financials and industrials detracted on a relative basis. Geographically, international businesses that are classified as US stocks were the largest...

RADNOR, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”).

LOS ANGELES , Nov. 14, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of the securities laws.

NEW YORK--(BUSINESS WIRE)---- $QURE #classactionlawsuit--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of uniQURE N.V. (“uniQURE” or the “Company”) (NASDAQ:QURE) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATIO...

LOS ANGELES , Nov. 11, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of the securities laws.

RADNOR, Pa. , Nov. 10, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V.

UniQure stock is rated a Buy with a $66 price target, offering upside after recent FDA pushback on AMT-130 Huntington's therapy trial design. AMT-130 is the first disease-modifying therapy for Huntington's, showing 75% slowing of disease progression and significant functional benefit in Phase 1/2 data. Modeling suggests a 78% probability of eventual approval (accelerated or post-Phase 3), with ...

uniQure N.V. ( QURE ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Chiara Russo - Senior Director of Investor Relations Matthew Kapusta - CEO & Executive Director Walid Abi-Saab - Chief Medical Officer Kylie O'Keefe - Chief Customer & Strategy Officer Christian Klemt - CFO, Principal Financial Officer & GM of Amsterdam Site Conference Call Participants Joseph Schwart...